Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Jenny DimakosYing CuiRobert W PlattChristel RenouxKristian B FilionAntonios Douros

Published in: Diabetes care (2023)

β-blockers could further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. β-blocker cardioselectivity did not seem to play a major role in this regard.

Keyphrases

angiotensin converting enzyme
type diabetes
early onset
angiotensin ii
glycemic control
insulin resistance
weight loss
skeletal muscle